TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35881980

Group type: EXPERIMENTAL
Intervention: Adaptations in research design and data collection due to COVID-19 pandemic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional quantitative and qualitative data collection and analysis
Number of subjects: 0
Study: 32534645

Group type: EXPERIMENTAL
Intervention: Antibiotic shunt
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Silver shunt
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard drain
Number of subjects: 276
Study: 35830484

Group type: EXPERIMENTAL
Intervention: Abdominal binder (n = 16)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 34
Study: 32615623

Group type: EXPERIMENTAL
Intervention: Telemedical services for exclusive remote treatment
Number of subjects: 217
Study: 36079092

Group type: EXPERIMENTAL
Intervention: Gait/Trunk Group (GTG) - robotic gait rehabilitation and balance with a robotic platform, 3 times/week for 12 sessions/month
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gait Group (GG) - robotic treatment for gait rehabilitation through an end-effector system
Number of subjects: 36
Study: 33092476

Group type: EXPERIMENTAL
Intervention: HIV prevalence among transgender women
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Residence in Asunción department
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 304
Study: 35837489

Group type: EXPERIMENTAL
Intervention: Oral triazolam
Number of subjects: 124

Group type: COMPARATOR
Intervention: IV midazolam
Number of subjects: 124
Study: 33403428

Group type: EXPERIMENTAL
Intervention: 10 ml 0.375% ropivacaine at T2, T5, and T8 levels
Number of subjects: 60
Study: 35260182

Group type: EXPERIMENTAL
Intervention: D1 Now intervention (agenda-setting tool, interactive messaging system, support worker)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: D1 Now intervention (agenda-setting tool, support worker)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 32586399

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) Solution for injection 10 μg/ml, administered as 0.8g/kg i.v. bolus followed by 0.113g.kg-1.h-1 i.v. infusion for 48 hours, then a maintenance dose of 0.057g.kg-1.h-1 i.v. until weaning or end of follow-up (max 30 days).
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with identical composition and dosage apart from the active substance.
Number of subjects: 60
Study: 36072908

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally 36 h, 24 h, and 12 h before surgery
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo orally at the same time points preoperatively
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 32283407

Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 35886553

Group type: EXPERIMENTAL
Intervention: Environmental factors (otitis, atopic dermatitis, premature delivery)
Number of subjects: 613
Study: 33615388

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dynamic exercise
Number of subjects: 12
Study: 32467347

Group type: EXPERIMENTAL
Intervention: Polygenic score for platelet count (223 SNPs)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Twelve platelet count-associated SNPs
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Three SNPs (rs10058074, rs210142, rs2836441)
Number of subjects: 959
Study: 32245308

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin per day for 24 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 34613361

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study: 33134378

Group type: EXPERIMENTAL
Intervention: Participants meeting SPRINT eligibility criteria (4,036 participants, 15.5%)
Number of subjects: 26093

Group type: EXPERIMENTAL
Intervention: Participants eligible for SPRINT not treated for hypertension (56.2%)
Number of subjects: 26093

Group type: EXPERIMENTAL
Intervention: Participants not previously considered to have hypertension (542 participants, 13.4%)
Number of subjects: 26093

Group type: EXPERIMENTAL
Intervention: Adults with hypertension potentially benefiting from treatment intensification (3,494 participants, 30.0%)
Number of subjects: 26093

Group type: EXPERIMENTAL
Intervention: Most common antihypertensive medication class being taken
Number of subjects: 26093
Study: 35751005

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with red and infrared LEDs (660 nm and 850 nm), 126 mW power, 75.6 J per point, applied once per day three times per week for 2 weeks.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 18
Study: 33021466

Group type: EXPERIMENTAL
Intervention: FTD/TPI
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 34866254

Group type: EXPERIMENTAL
Intervention: Home visitation program using the Problem-Solving Tools for PPD (PST4PPD) model delivered by master's level social workers
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard treatment with a psychiatrist
Number of subjects: 118
Study: 32170754

Group type: EXPERIMENTAL
Intervention: ABCNet
Number of subjects: 38

Group type: COMPARATOR
Intervention: DeepMedic
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3D U-Net
Number of subjects: 38

Group type: COMPARATOR
Intervention: V-Net
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dense V-Net
Number of subjects: 38
Study: 36094772

Group type: EXPERIMENTAL
Intervention: Fampridine plus intravenous methylprednisolone (IVMP) for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo plus intravenous methylprednisolone (IVMP) for 7 days
Number of subjects: 30
Study: 33619807

Group type: EXPERIMENTAL
Intervention: Myofiber strain (Eff)
Number of subjects: 30
Study: 32217211

Group type: EXPERIMENTAL
Intervention: Medial arch support foot orthoses (FOs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flat 2-mm-thick insole (Control)
Number of subjects: 30
Study: 36184068

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks
Number of subjects: 805

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 805
Study: 33655944

Group type: EXPERIMENTAL
Intervention: MOOC-based blended learning
Number of subjects: 181

Group type: COMPARATOR
Intervention: Face-to-face classroom teaching
Number of subjects: 181
Study: 35739544

Group type: EXPERIMENTAL
Intervention: Reflex locomotion therapy (EGrlt)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Passive mobilizations with gentle joint compression (EGpmc)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Massage (CG)
Number of subjects: 106
Study: 33185181

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG testing using ELISA techniques
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG testing
Number of subjects: 133
Study: 32919855

Group type: EXPERIMENTAL
Intervention: Stereoscopic display
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonstereo display
Number of subjects: 22
Study: 34535473

Group type: EXPERIMENTAL
Intervention: Pulse oximetry intervention for identifying hypoxaemia in children with severe pneumonia.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical signs of severe pneumonia (fast breathing and/or chest in-drawing, and one or more danger signs).
Number of subjects: 0
Study: 34269453

Group type: EXPERIMENTAL
Intervention: Low-titer group O whole-blood (LTOWB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard blood component transfusion
Number of subjects: 36
Study: 32434001

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy platelet factor 4 (tertile 3)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Pre-pregnancy platelet factor 4 (tertile 3) in placebo group
Number of subjects: 584

Group type: COMPARATOR
Intervention: Pre-pregnancy platelet factor 4 (tertile 3) in aspirin group
Number of subjects: 584
Study: 35263518

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (1.1 GBq) after injections of recombinant human thyrotropin
Number of subjects: 730

Group type: COMPARATOR
Intervention: No postoperative radioiodine
Number of subjects: 730
Study: 33180039

Group type: EXPERIMENTAL
Intervention: Workshop training (46 students)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Untrained group (44 students)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Second assessment of trained participants (n=80)
Number of subjects: 90
Study: 36183062

Group type: EXPERIMENTAL
Intervention: Demodex-positive young patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Demodex-positive elderly patients
Number of subjects: 202

Group type: COMPARATOR
Intervention: Elderly Demodex-positive patients vs. young patients
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Elderly Demodex-positive patients
Number of subjects: 202
Study: 33534804

Group type: EXPERIMENTAL
Intervention: Synthetic pheromone + insecticide
Number of subjects: 8
Study: 35725624

Group type: EXPERIMENTAL
Intervention: 2GETHER: a relationship education and HIV prevention program, delivered face-to-face in a university setting, composed of two group sessions and two individualized skills coaching sessions.
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control condition based on a well-validated positive affect enhancement program.
Number of subjects: 256
Study: 32020635

Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 58
Study: 34775577

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg daily for 12 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 33260063

Group type: EXPERIMENTAL
Intervention: Criscy™ (biosimilar recombinant growth hormone)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Genotropin™ (originator recombinant growth hormone)
Number of subjects: 81
Study: 32349835

Group type: EXPERIMENTAL
Intervention: RemedRugby (RR)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Touch Rugby (TR)
Number of subjects: 87
Study: 34739197

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (initial dose 12.5 mg/day, max 50 mg/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 160
Study: 32576258

Group type: EXPERIMENTAL
Intervention: Extended 6-day treatment with artemether-lumefantrine and a single low-dose primaquine
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard 3-day treatment with artemether-lumefantrine (control)
Number of subjects: 280
Study: 35997730

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 9711

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg/d)
Number of subjects: 9711
Study: 34663636

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (switched to upadacitinib at week 24)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 0
Study: 33380535

Group type: EXPERIMENTAL
Intervention: Fendrix® (t = 0, 4, 8, 24 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Engerix® (t = 0, 4, 24 weeks)
Number of subjects: 48
Study: 34050419

Group type: EXPERIMENTAL
Intervention: Short-stitch technique (USP 2-0 single thread)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Long-stitch technique (USP 1 double loop)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Short-stitch technique
Number of subjects: 425
Study: 33734057

Group type: EXPERIMENTAL
Intervention: RPH-104 treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 35254199

Group type: EXPERIMENTAL
Intervention: Ganilever pre-filled syringe (PFS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Orgalutran
Number of subjects: 236
Study: 35241174

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study: 35247512

Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet-rich plasma (Lp-PRP) injections (3 injections at the tendon repair site during surgery, at days 7 and 14 after surgery)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (double-row suture-bridge arthroscopic rotator cuff repair alone)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet-rich plasma (Lp-PRP) injections
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 32888985

Group type: EXPERIMENTAL
Intervention: Alginate hydrogel containing 0.5% hydrogen sulfide (H2S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alginate hydrogel containing higher concentrations of H2S
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alginate hydrogel (unspecified concentration)
Number of subjects: 0
Study: 36198291

Group type: EXPERIMENTAL
Intervention: 10-h time-restricted eating (TRE)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 137
Study: 33705623

Group type: EXPERIMENTAL
Intervention: FAC plus Simvastatin (40 mg/d orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FAC plus placebo (40 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAC plus Simvastatin
Number of subjects: 0
Study: 33183671

Group type: EXPERIMENTAL
Intervention: Power exercise training (PT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-exercise control (Con)
Number of subjects: 24
Study: 34914150

Group type: EXPERIMENTAL
Intervention: Habitual exposure to violent video games
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Antisocial media content
Number of subjects: 402

Group type: COMPARATOR
Intervention: Short-term violent gameplay
Number of subjects: 402
Study: 34165258

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Participants with alcohol dependence
Number of subjects: 440
Study: 33934038

Group type: EXPERIMENTAL
Intervention: Face-to-face simulation education program (F2F)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Web-based simulation education program (WB)
Number of subjects: 126
Study: 33740345

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intra-articular platelet-rich plasma (PRP)
Number of subjects: 200
Study: 35274286

Group type: EXPERIMENTAL
Intervention: Stress ball
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Audio-visual eyeglasses
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (basic behaviour guidance without distraction)
Number of subjects: 123
Study: 33766051

Group type: EXPERIMENTAL
Intervention: Physical Activity and Sleep Health (PAS)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Wait-list Control (CON)
Number of subjects: 440
Study: 32272923

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 60
Study: 36082522

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 300
Study: 32201897

Group type: EXPERIMENTAL
Intervention: JNJ-8678
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 35170192

Group type: EXPERIMENTAL
Intervention: bremelanotide (3 times daily for 15 days)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: bremelanotide (twice-daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: bremelanotide (3 times daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 57
Study: 33773535

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 48
Study: 33223974

Group type: EXPERIMENTAL
Intervention: Scoring/cutting balloons (SCB)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Rotational atherectomy (RA)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both SCB and RA
Number of subjects: 115
Study: 35893857

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micronutrient tablets (Tablets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fortified beverage (Beverage)
Number of subjects: 0
Study: 33762662

Group type: EXPERIMENTAL
Intervention: Seldinger technique by inexperienced practitioners (IE-S)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique by inexperienced practitioners (IE-MS)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Seldinger technique by experienced practitioners (E-S)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique by experienced practitioners (E-MS)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Comparison of both techniques in inexperienced practitioners
Number of subjects: 308

Group type: COMPARATOR
Intervention: Comparison of both techniques in experienced practitioners
Number of subjects: 308
Study: 32825535

Group type: EXPERIMENTAL
Intervention: Physical Activity Counseling (PAC) for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (instructions about FITT in one meeting)
Number of subjects: 22
Study: 36451623

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh) plus repositioning therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Light touch therapy (LTT) plus repositioning therapy
Number of subjects: 96
Study: 33509413

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) implemented by trained staff of opioid treatment programs (OTPs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New methods of medication delivery implemented by OTPs
Number of subjects: 0
Study: 33838579

Group type: EXPERIMENTAL
Intervention: Algorithm Guided Treatment started with escitalopram (AGT-E)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Algorithm Guided Treatment started with mirtazapine (AGT-M)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 980
Study: 34343545

Group type: EXPERIMENTAL
Intervention: Maxillofacial and oral massage (MOM)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Routine oral care and medication
Number of subjects: 158
Study: 32334516

Group type: EXPERIMENTAL
Intervention: Work Stress Questionnaire (WSQ) combined with general practitioner (GP) training and GP feedback at consultation.
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 271
Study: 35924970

Group type: EXPERIMENTAL
Intervention: HK-PS23
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 32079426

Group type: EXPERIMENTAL
Intervention: circRNA expression profile in SCLC tissues
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: circ-STXBP5L
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bioinformatics analysis of circ-STXBP5L
Number of subjects: 6
Study: 33280419

Group type: EXPERIMENTAL
Intervention: Socio-economic variables (age, education, marital status, lactation period)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Socio-economic variables (age, education, being housewife)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Family size
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Socio-economic variables (marital status, age, lactation period)
Number of subjects: 423
Study: 32710606

Group type: EXPERIMENTAL
Intervention: Avoidance group (received stop cue and could press stop button)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (received same instructions but could not avoid full heat intensity)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (after the test phase where avoidance was unavailable)
Number of subjects: 66
Study: 36052694

Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase (LDH) levels as a prognostic marker for mortality in COVID-19 patients
Number of subjects: 843
Study: 32162741

Group type: EXPERIMENTAL
Intervention: Topical red clover oil (20 drops twice a day for 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Olive oil (control group, 20 drops twice a day for 4 weeks)
Number of subjects: 80
Study: 35984574

Group type: EXPERIMENTAL
Intervention: Low MAP target (65 to 70 mmHg)
Number of subjects: 747

Group type: COMPARATOR
Intervention: High MAP target (80 to 85 mmHg)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Presence of mottling ≥ 6 hours during the first 24 hours
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Mottling < 6 hours and lactate ≥ 2 mmol/L
Number of subjects: 747
Study: 34774225

Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg intravenously every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks for up to 2 years.
Number of subjects: 119
Study: 33141524

Group type: EXPERIMENTAL
Intervention: Early Active Rehabilitation (initiated 2 weeks after injury)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Active Rehabilitation (initiated 4 weeks after injury)
Number of subjects: 20
Study: 34464551

Group type: EXPERIMENTAL
Intervention: IRHD-WG
Number of subjects: 10

Group type: COMPARATOR
Intervention: IRHD-XCP
Number of subjects: 10
Study: 34414984

Group type: EXPERIMENTAL
Intervention: Midazolam combined with palonosetron (group MP)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Palonosetron alone (group P)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups (MP and P)
Number of subjects: 88
Study: 32301492

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 2084
Study: 34797778

Group type: EXPERIMENTAL
Intervention: 3-g gluten challenge
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham (rice flour)
Number of subjects: 60
Study: 33744225

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU/weekly for eight weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35904229

Group type: EXPERIMENTAL
Intervention: VCMX
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SCTG
Number of subjects: 20